{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Dalbavancin",
    "query": {
      "intervention": "IV Dalbavancin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Dalbavancin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T19:35:55.498Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02814916",
      "title": "Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Methicillin-Resistant Staphylococcus Aureus",
        "Bacterial Infections",
        "Staphylococcal Skin Infections"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Oxacillin",
          "type": "DRUG"
        },
        {
          "name": "Flucloxacillin",
          "type": "DRUG"
        },
        {
          "name": "Cefadroxil",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 199,
      "start_date": "2017-03-30",
      "completion_date": "2024-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 15,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02814916"
    },
    {
      "nct_id": "NCT00678106",
      "title": "Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-09",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2009-10-12",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Louisville, Kentucky • Cleveland, Ohio",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678106"
    },
    {
      "nct_id": "NCT02940730",
      "title": "Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infectious Peritonitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin via Intravenous Administration",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin via Intraperitoneal Administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-01",
      "completion_date": "2018-06-18",
      "has_results": true,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02940730"
    },
    {
      "nct_id": "NCT03148756",
      "title": "Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endocarditis",
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-05-12",
      "completion_date": "2017-08-04",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "Ft. Pierce, Florida",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03148756"
    },
    {
      "nct_id": "NCT01431339",
      "title": "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "IV Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin/Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 739,
      "start_date": "2011-07",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-12",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 30,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431339"
    },
    {
      "nct_id": "NCT05977868",
      "title": "Comparing Oral Versus Parenteral Antimicrobial Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endovascular Infection",
        "Bone and Joint Infection",
        "Skin and Soft Tissue Infection",
        "Pulmonary Infection",
        "Gastrointestinal Infection",
        "Genitourinary Infection"
      ],
      "interventions": [
        {
          "name": "Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid",
          "type": "DRUG"
        },
        {
          "name": "Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2023-08-04",
      "completion_date": "2025-02-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05977868"
    },
    {
      "nct_id": "NCT03233438",
      "title": "Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bacterial Infections",
        "Acute Bacterial Skin and Skin Structure Infection"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Usual Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2017-07-24",
      "completion_date": "2018-10-30",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233438"
    },
    {
      "nct_id": "NCT06266494",
      "title": "Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Frostbite"
      ],
      "interventions": [
        {
          "name": "Long-Acting silver dressings",
          "type": "DEVICE"
        },
        {
          "name": "Aloe Vera",
          "type": "OTHER"
        },
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-01",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2024-05-13",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06266494"
    },
    {
      "nct_id": "NCT01339091",
      "title": "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin / Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 573,
      "start_date": "2011-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-01-31",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 55,
      "location_summary": "Anaheim, California • Azusa, California • Bellflower, California + 50 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Carmel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339091"
    },
    {
      "nct_id": "NCT02269644",
      "title": "A P3 Comparator Trial in Community Acquired Bacterial Pneumonia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Linezolid Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-09-17T19:35:55.498Z",
      "location_count": 1,
      "location_summary": "Butte, Montana",
      "locations": [
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269644"
    }
  ]
}